← back to search

Joud Hajjar

Texas Children's Hospital · US
Area of research
Immunology · Oncology
Research interest
Research interests include Immunodeficiency and Autoimmune Disorders, Cancer Immunotherapy and Biomarkers, Immune Cell Function and Interaction, and Chronic Lymphocytic Leukemia Research.
h-index
20
citations
2,046
works
117
NIH funding
primary concept
email

Recent publications

Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patients
The Journal of Experimental Medicine 2021cited by 73position: middledoi
Rubella Virus Infected Macrophages and Neutrophils Define Patterns of Granulomatous Inflammation in Inborn and Acquired Errors of Immunity
Frontiers in Immunology 2021cited by 40position: middledoi
Phase 2 study of pembrolizumab in patients with advanced rare cancers
Journal for ImmunoTherapy of Cancer 2020cited by 130position: middledoi
T-cell agonists in cancer immunotherapy
Journal for ImmunoTherapy of Cancer 2020cited by 119position: lastdoi
Diagnostic interpretation of genetic studies in patients with primary immunodeficiency diseases: A working group report of the Primary Immunodeficiency Diseases Committee of the American Academy of Allergy, Asthma & Immunology
Journal of Allergy and Clinical Immunology 2019cited by 95position: middledoi
Use of Genetic Testing for Primary Immunodeficiency Patients
Journal of Clinical Immunology 2018cited by 93position: middledoi
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
Investigational New Drugs 2017cited by 182position: middledoi
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept
Investigational New Drugs 2017cited by 119position: middledoi
Targeting the indoleamine 2,3-dioxygenase pathway in cancer
Journal for ImmunoTherapy of Cancer 2015cited by 332position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Aung Naing · The University of Texas MD Anderson Cancer Center4 papers (2015–2020)María E. Suarez‐Almazor · The University of Texas MD Anderson Cancer Center2 papers (2017–2017)Jordan S. Orange · Rockefeller University2 papers (2018–2019)Ajay Sheshadri · The University of Texas Health Science Center at Houston2 papers (2017–2017)Padmanee Sharma · The University of Texas MD Anderson Cancer Center2 papers (2017–2017)Troy R. Torgerson · Allen Institute for Immunology2 papers (2018–2019)Funda Meric‐Bernstam · Breast Cancer Care2 papers (2017–2017) · 2 papers (2017–2017)Rivka R. Colen · The University of Texas MD Anderson Cancer Center2 papers (2017–2017)Takeo Fujii · Center for Cancer Research2 papers (2017–2017)Kenneth R. Hess · The University of Texas MD Anderson Cancer Center2 papers (2017–2017)Monica G. Lawrence · University of Virginia2 papers (2018–2019)David S. Hong · The University of Texas MD Anderson Cancer Center2 papers (2017–2017)Janet Chou · Harvard University2 papers (2018–2019)Tito R. Mendoza · Patient-Centered Outcomes Research Institute2 papers (2017–2017)Lisa Kobrynski · Emory University2 papers (2018–2019)Vivek Subbiah · International Drug Development2 papers (2017–2017)Siqing Fu · The University of Texas MD Anderson Cancer Center2 papers (2017–2017)Mehmet Asım Bilen · Emory Healthcare2 papers (2017–2017) · 2 papers (2017–2017)